检索结果-南通市图书馆

维普期刊数据库

burkitt’s lymphoma presenting with rapidly and multi-organ involvement: A case presentation

在线全文

学校读者我要写书评

暂无评论

Case Reports in Clinical Medicine 2013年第4期2卷 242-245页

作者： Ilhami Berber Mehmet Ali Erkurt Mustafa Koroglu Irfan Kuku Emin Kaya Recep Bentli Departman of General Medicine Inonu University Malatya Turkey Department of Hematology School of Medicine Inonu University Malatya Turkey

burkitt lymphoma is an aggressive lymphoma and its clinical, immunologic, chemical features are well-known. burkitt lymphoma is in highgrade lymphomas and can spread very rapidly. burkitt lymphoma has been difficult to be cured with conventional chemotherapy for adults. Early autologous bone marrow should be kept in mind in first remission BL. We presented a case of presenting with rapid and multi organ involvement with BL. A 55-year-old male patient responded to the conventional chemotherapy for short-term and died 9 months after diagnosis because of relapse of burkitt lymphoma.

关键词： burkitt Lymphoma Rapidly Bone Marrow Transplantation

burkitt淋巴瘤(Namalva)细胞RNA对白血病细胞系(J6-1)增殖的影响

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中国病理生理杂志 1993年第2期 132-169页

作者：毕富勇李牧法祥光贾丽吴克复皖南医学院生化教研室中国医学科学院液血学研究所芜湖 241001 中国医学科学院液血学研究所

近年来,人们从理论上推测反义RNA在细胞增殖过程中起负调节因子作用,但有关实验证据不多。我们用本所已有的血源细胞系J6-1及Namalva细胞对此进行了探索性研究,以期寻找抑制肿瘤细胞增殖的新物质。结果证明,由Namalva细胞提取的低分子RN... 详细信息

近年来,人们从理论上推测反义RNA在细胞增殖过程中起负调节因子作用,但有关实验证据不多。我们用本所已有的血源细胞系J6-1及Namalva细胞对此进行了探索性研究,以期寻找抑制肿瘤细胞增殖的新物质。结果证明,由Namalva细胞提取的低分子RNA对J6-1细胞的增殖有抑制作用。

关键词：细胞细胞增殖低分子抑制作用基因互作 J6-1 Namalva burkitt 淋巴瘤 RNA

Rituximab Improves Overall Survival in Patients Treated with CODOX-M/IVAC for burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and BL (BCL-U): A Single Center Experience and Review of the Literature

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Journal of Cancer Therapy 2015年第1期6卷 1-11页

作者： A. Prica A. Pratzer M. Cheung K. Thompson E. Piliotis N. L. Berinstein K. Imrie R. Pradhan A. Vyas Z. Ghorab D. Good L. Zhang R. Buckstein Hematology/Oncology Odette Cancer Centre Sunnybrook Health Sciences Centre Toronto Canada Feinberg School of Medicine Northwestern University Chicago USA Schulich School of Medicine and Dentistry University of Western Ontario London Canada Department of Pharmacy Sunnybrook Health Sciences Centre Toronto Canada

Background: Dose-modified (dm) CODOX-M/IVAC is commonly used for burkitt lymphoma (BL) and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma (DLBCL) and BL (BCL-U;previously burkitt-like lymphoma-BLL). Methods: We evaluated the clinical characteristics, outcomes and prognostic markers in patients treated with dmCODOX-M/IVAC+/- rituximab (R) at a single academic center. Results: 31 patients with BL (n = 21) or BCL-U (n = 10) were included. The median age was 45, and 90% were high risk. The 2-year overall survival (OS) and progression-free survival (PFS) were 69% and 62%, respectively, with no differences between BL and BCL-U. By multivariable analysis, rituximab use was significantly associated with improved OS (Hazard Ratio 0.15;95% CI 0.04 - 0.56) while elevated LDH (Hazard Ratio 2.84, 95% CI 1.52 - 5.29) and rituximab use (Hazard Ratio 0.054, 95% CI 0.01 - 0.32) predicted PFS. Conclusion: DmCODOX-M/IVAC+/- R chemotherapy provides equivalent survival for both BL and BCL-U patients. The addition of rituximab improves overall and progression free survival and is recommended.

关键词： burkitt Lymphoma burkitt-Like Lymphoma CODOX-M/IVAC MYC Rituximab

Tumor Lysis Syndrome in the Course of burkitt Lymphoma Revealed by Medullar Compression

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Open Journal of Modern Neurosurgery 2019年第4期9卷 429-435页

作者： L. Boukassa S. B. Kinata Bambino O. B. Ngackosso K. Mavoungou Biatsi H. B. Ekouele-Mbaki P. Mawanza Department of Surgery Division of Neurosurgery Brazzaville Academic Hospital Brazzaville Republic of Congo Department of Anesthesia-Reanimation Brazzaville Academic Hospital Brazzaville Republic of Congo

Background: Tumor lysis syndrome is unknown to many neurosurgical teams. A dreaded complication, especially in the course of hematological malignancies, like it was the case in two of our patients operated for spinal cord compression by burkitt’s lymphoma. Objectives: To describe the clinical and biological presentation of this potentially fatal complication, which can be improved by early preventive or curative treatments. Case Reports: Patient 1: A 49-year-old woman was admitted for vertebral and intercostal pain and paraparesis. Myelography revealed epidural medullary compression at the 7th thoracic vertebrae (Th7) level. Patient 2: A 67-year-old woman was admitted for cervico-thoracic pain and paraparesis. MRI showed posterior epidural medullary compression between the 1st thoracic vertebrae (Th1) and 5th thoracic vertebrae (Th5). In both cases, an urgent decompressive laminectomy was performed. They had also received postoperative corticosteroid therapy. The multi-visceral failure occurred on the 1st day (D1) and 3rd day (D3) postoperatively, respectively. In the absence of adequate management, the outcome was fatal for the two patients respectively at D3 and D5 postoperatively. This syndrome was retained in the presence of glucocorticoid (triggering factor) and the histological result in favor of burkitt lymphoma (target disease). Conclusion: Malignant hemopathies is a common cause of spinal cord compressions. From these two cases, the importance of biological and clinical surveillance emerges, with patients requiring urgent management for radiculo-medullar tumor compression.

关键词： Tumor Lysis Syndrome Spinal Cord Compression burkitt Lymphoma

615裸鼠体内建立的人burkitt淋巴瘤细胞株

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中国肿瘤临床 1988年第2期15卷 116-118+2页

作者：褚建新应红光丁立宋玉华吴克复孙靖安瑞平许全明王秀清中国药品生物制品研究所中国医学科学院血液学研究所

本文首先报道了利用国内建立的615裸鼠(615/PBI-nu)成功地移植人burkitt淋巴瘤Namalva细胞系。这种恶性淋巴瘤细胞系已在裸鼠间连续传代7代,自第5代后移植成功率为100％。移植于皮下的瘤块呈进行性生长,并有区域淋巴结转移。肿瘤细胞染... 详细信息

本文首先报道了利用国内建立的615裸鼠(615/PBI-nu)成功地移植人burkitt淋巴瘤Namalva细胞系。这种恶性淋巴瘤细胞系已在裸鼠间连续传代7代,自第5代后移植成功率为100％。移植于皮下的瘤块呈进行性生长,并有区域淋巴结转移。肿瘤细胞染色体分析属人的体细胞核型。用单克隆抗体免疫过氧化酶(ABC法)和间接免疫荧光法检测,体外培养的和裸鼠体内生长的瘤细胞都具有HLA-DR、RFB4和RFB6抗原,表明该瘤细胞属人的B-细胞淋巴瘤。移植于裸鼠体内生长的瘤细胞比体外生长更好。瘤细胞电镜观察,于瘤细胞间可见许多病毒样颗粒,根据其形态可能为EB病毒。裸鼠体内burkitt淋巴瘤细胞株的建立为研究人类恶性淋巴瘤提供了有用工具。

关键词：裸鼠细胞系体外培养体内移植 burkitt 瘤细胞株淋巴瘤淋巴淋巴系统

小儿免疫缺陷病毒感染的burkitt淋巴瘤

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

国际儿科学杂志 1989年第5期 274-275页

作者：李薇

小儿艾滋病的主要临床体征是生长停滞,机会感染和淋巴性间质性肺炎。最近报导成人人免疫缺陷病毒（HIV）感染时,淋巴肉瘤、非何杰金淋巴瘤的发病数正在增多。本文报道一例儿童HIV感染与EB病毒（EBV）相关的B细胞burkitt淋巴瘤的临床、... 详细信息

小儿艾滋病的主要临床体征是生长停滞,机会感染和淋巴性间质性肺炎。最近报导成人人免疫缺陷病毒（HIV）感染时,淋巴肉瘤、非何杰金淋巴瘤的发病数正在增多。本文报道一例儿童HIV感染与EB病毒（EBV）相关的B细胞burkitt淋巴瘤的临床、病理及分子学特征。病例 4岁黑人男孩。足月产,其母有静脉滥用药物史。以患儿发热数日,腹痛、呕吐、厌食、腹围增大入院。2岁以内健康。曾以怀疑病毒性肺炎住院。有全身淋巴结肿大、肝大、生长停滞。免疫学检查:多克隆高γ球蛋白血症,辅助T细胞（T;）与抑制T细胞（T;）比值倒置。血清HIV抗体阳性。此次以怀疑病毒性肺炎再次住院。查体:无热,营养低下,身

关键词：淋巴瘤 HIV burkitt EBV 小儿淋巴结肿大

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

burkitt淋巴瘤的超声表现：个例报告

北铁医刊 1990年第13期 35-36页

作者：陈松朱晓兰

burkitt淋巴瘤细胞的c—myc致癌基因在两侧都可发生染色体易位

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

国外医学(肿瘤学分册) 1984年第5期 304-305页

作者：陈黎丹

许多burkitt 淋巴瘤(BL)细胞的染色体易位都是将c-myc 致癌基因为免疫球蛋白基因相连接.人BL 易位有三种情况,最多的一种是t(8:14),其他还有t(2:8)和t(8:22).带有t(8:14)易位的BL 细胞其c-myc 从染色体8易位至染色体14(14q~+)的Ig 重链... 详细信息

许多burkitt 淋巴瘤(BL)细胞的染色体易位都是将c-myc 致癌基因为免疫球蛋白基因相连接.人BL 易位有三种情况,最多的一种是t(8:14),其他还有t(2:8)和t(8:22).带有t(8:14)易位的BL 细胞其c-myc 从染色体8易位至染色体14(14q~+)的Ig 重链恒定区(IgHCμ),同时重链可

关键词：淋巴瘤致癌基因细胞株染色体易位 myc burkitt

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

burkitt氏淋巴瘤

国外医学.耳鼻咽喉科学分册 1988年第1期 37-38页

作者：李乃麟

非何杰金氏淋巴瘤(NHL)是小儿常见的头颈部实体肿瘤,病程进展迅速,但由于过去15年化疗的进步,本病预后已得到改进。burkitt氏淋巴瘤(BL)属B细胞型NHL,可分为地方性(非洲)与非地方性(美洲)两类。

关键词：淋巴瘤 BL 非洲美洲 burkitt 网状细胞 NHL